Senberk Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.70 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
About Senberk Pharmaceuticals
Senberk Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 January 2015 and has a history of Ten years and one month. Its registered office is in Cuttack, Odisha, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M, as per Ministry of Corporate Affairs (MCA) records.
Vijaya Choudhary, Sujit Singh, Biswa Dash, and One other member serve as directors at the Company.
Company Details
- Location
Cuttack, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33112OR2015PTC018628
- Company No.
018628
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jan 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Senberk Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Biswa Dash  | Managing Director | 20-Jan-2015 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vijaya Choudhary | Director | 07-Jan-2019 | Current |
| Sujit Singh | Director | 20-Jan-2015 | Current |
| Arunjyoti Ghosal | Director | 20-Jan-2015 | Current |
Financial Performance of Senberk Pharmaceuticals.
Senberk Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Senberk Pharmaceuticals?
In 2017, Senberk Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fosen Pharmaceuticals Private LimitedBiswa Dash is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Senberk Pharmaceuticals?
Senberk Pharmaceuticals has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Senberk Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Senberk Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
